Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors

Fig. 4

Spectrum of acquired resistance mechanisms in dependence on primary driver mutation. Frequencies of acquired resistance mechanisms under reversible (a) and irreversible (b) EGFR TKI therapy on the background of primary driver mutation. Note, section p.T790M covers only patients with T790M as exclusive resistance mechanism. Section of multiple resistance mechanisms includes patients with p.T790M plus MET or HER2 amplification

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us